Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
Go back to Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias| AGIOS PHARM (NASDAQ: AGIO) | Delayed: 29.46 +0.74 (2.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.72 | 52 Week High | $71.49 | |||
| Open | $28.80 | 52 Week Low | $33.50 | |||
| Day High | $30.23 | P/E | N/A | |||
| Day Low | $28.51 | EPS | $-1.18 | |||
| Volume | 1,141,118 | |||||
